Literature DB >> 26666924

Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis.

Ibai Los-Arcos1, Carles Pigrau2, Dolors Rodríguez-Pardo2, Nuria Fernández-Hidalgo2, Antonia Andreu3, Nieves Larrosa3, Benito Almirante2.   

Abstract

This is a retrospective study of 15 difficult-to-treat (i.e., exhibiting previous failure, patient side effects, or resistance to ciprofloxacin and co-trimoxazole) chronic bacterial prostatitis infections (5 patients with multidrug-resistant Enterobacteriaceae [MDRE]) receiving fosfomycin-tromethamine at a dose of 3 g per 48 to 72 h for 6 weeks. After a median follow-up of 20 months, 7 patients (47%) had a clinical response, and 8 patients (53%) had persistent microbiological eradication; 4/5 patients with MDRE isolates achieved eradication. There were no side effects. Fosfomycin-tromethamine is a possible alternative therapy for chronic bacterial prostatitis.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26666924      PMCID： PMC4776017          DOI： 10.1128/AAC.02611-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline.

Authors:  Burke A Cunha; Arthur Gran; Muhammad Raza
Journal:  Int J Antimicrob Agents       Date:  2015-01-20       Impact factor: 5.283

2.  Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?

Authors:  B J Gardiner; A A Mahony; A G Ellis; N Lawrentschuk; D M Bolton; P T Zeglinski; A G Frauman; M L Grayson
Journal:  Clin Infect Dis       Date:  2013-10-28       Impact factor: 9.079

3.  Editorial Commentary: Fosfomycin: The Current Status of the Drug.

Authors:  Matthew E Falagas; Petros I Rafailidis
Journal:  Clin Infect Dis       Date:  2015-06-10       Impact factor: 9.079

4.  Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.

Authors:  M Lindsay Grayson; Nenad Macesic; Janine Trevillyan; Andrew G Ellis; Phillip T Zeglinski; Nicholas H Hewitt; Bradley J Gardiner; Albert G Frauman
Journal:  Clin Infect Dis       Date:  2015-06-10       Impact factor: 9.079

5.  Value of semen culture in the diagnosis of chronic bacterial prostatitis: a simplified method.

Authors:  Alberto Budía; José Luis Palmero; Enric Broseta; Susana Tejadillos; Antonio Benedicto; José A Queipo; Miguel Gobernado; J Fernando Jiménez Cruz
Journal:  Scand J Urol Nephrol       Date:  2006

6.  Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.

Authors:  Husnu Pullukcu; Meltem Tasbakan; Oguz Resat Sipahi; Tansu Yamazhan; Sohret Aydemir; Sercan Ulusoy
Journal:  Int J Antimicrob Agents       Date:  2007-01       Impact factor: 5.283

7.  Diagnosing and treating chronic prostatitis: do urologists use the four-glass test?

Authors:  M McNaughton Collins; F J Fowler; D B Elliott; P C Albertsen; M J Barry
Journal:  Urology       Date:  2000-03       Impact factor: 2.649

8.  The impact of biofilm-producing bacteria on chronic bacterial prostatitis treatment: results from a longitudinal cohort study.

Authors:  Riccardo Bartoletti; Tommaso Cai; Gabriella Nesi; Sara Albanese; Francesca Meacci; Sandra Mazzoli; Kurt Naber
Journal:  World J Urol       Date:  2013-08-06       Impact factor: 4.226

Review 9.  Antimicrobial therapy for chronic bacterial prostatitis.

Authors:  Gianpaolo Perletti; Emanuela Marras; Florian M E Wagenlehner; Vittorio Magri
Journal:  Cochrane Database Syst Rev       Date:  2013-08-12

Review 10.  Bacterial prostatitis.

Authors:  Florian M E Wagenlehner; Adrian Pilatz; Thomas Bschleipfer; Thorsten Diemer; Thomas Linn; Andreas Meinhardt; Undraga Schagdarsurengin; Temujin Dansranjavin; Hans-Christian Schuppe; Wolfgang Weidner
Journal:  World J Urol       Date:  2013-03-22       Impact factor: 4.226
View more
  11 in total

1.  Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully.

Authors:  Vrushali Patwardhan; Sarman Singh
Journal:  Int Urol Nephrol       Date:  2017-06-14       Impact factor: 2.370

2.  Potential Use of Fosfomycin-Tromethamine for Treatment of Recurrent Campylobacter Species Enteritis.

Authors:  Juan Aguilar-Company; Ibai Los-Arcos; Carles Pigrau; Dolors Rodríguez-Pardo; María Nieves Larrosa; Virginia Rodríguez-Garrido; Denisse Sihuay-Diburga; Benito Almirante
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

3.  Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies.

Authors:  Tanya Zapolskaya; Sarah Perreault; Dayna McManus; Jeffrey E Topal
Journal:  Support Care Cancer       Date:  2018-01-10       Impact factor: 3.603

4.  Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.

Authors:  Nayara Helisandra Fedrigo; Josmar Mazucheli; James Albiero; Danielle Rosani Shinohara; Fernanda Gomes Lodi; Ana Cristina Dos Santos Machado; Sherwin K B Sy; Maria Cristina Bronharo Tognim
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

5.  Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales.

Authors:  Kévin Bouiller; Souheil Zayet; Paul-Emile Lalloz; Anaïs Potron; Vincent Gendrin; Catherine Chirouze; Timothée Klopfenstein
Journal:  Antibiotics (Basel)       Date:  2022-02-03

6.  Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study.

Authors:  Philippa C Matthews; Lucinda K Barrett; Stephanie Warren; Nicole Stoesser; Mel Snelling; Matthew Scarborough; Nicola Jones
Journal:  BMC Infect Dis       Date:  2016-10-11       Impact factor: 3.090

Review 7.  Oral Fosfomycin for the Treatment of Acute and Chronic Bacterial Prostatitis Caused by Multidrug-Resistant Escherichia coli.

Authors:  George G Zhanel; Michael A Zhanel; James A Karlowsky
Journal:  Can J Infect Dis Med Microbiol       Date:  2018-01-30       Impact factor: 2.471

8.  Oral fosfomycin for the treatment of chronic bacterial prostatitis.

Authors:  Ilias Karaiskos; Lambrini Galani; Vissaria Sakka; Aikaterini Gkoufa; Odysseas Sopilidis; Dimitrios Chalikopoulos; Gerasimos Alivizatos; Eleni Giamarellou
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

9.  Antibiotic therapy of chronic bacterial prostatitis is more effective considering antibiotic susceptibility of all pathogens isolated.

Authors:  Mikhail I Kogan; Khalid S Ibishev; Yulia L Naboka; Irina A Gudima; Akhmed Kh Ferzauli; Ruslan S Ismailov; Kurt G Naber
Journal:  Investig Clin Urol       Date:  2022-04-05

10.  Ceftriaxone for the Treatment of Chronic Bacterial Prostatitis: A Case Series and Literature Review.

Authors:  Sander G Kuiper; Maarten Ploeger; Erik B Wilms; Marleen M van Dijk; Emiel Leegwater; Robert A G Huis In't Veld; Cees van Nieuwkoop
Journal:  Antibiotics (Basel)       Date:  2022-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.